Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $5 | $5 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $4 | $4 | $4 | $4 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $2 |
| Operating Income | $1 | $1 | $2 | $2 |
| % Margin | 25.3% | 28.5% | 31.6% | 30.8% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | $2 | $1 | $2 | $2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $4 | $1 | $2 | $2 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS | 6.98 | 2.31 | 2.46 | 2.41 |
| % Growth | 202.2% | -6.1% | 2.1% | – |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $2 | $2 | $2 | $2 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |